Elastase Inhibitor Preparation via Borylation for Extended Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current elastase inhibitors have short in vivo exposure times and are rapidly eliminated, which limits their efficacy in treating chronic obstructive pulmonary disease and other inflammatory conditions.
Innovation Solution
A process for preparing an elastase inhibitor compound using specific borylation, acidification, and condensation reactions with controlled conditions, including the use of isobutyl boronic acid and trifluoroacetic acid, to enhance reaction yield and stability, allowing for extended in vivo exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing elastase inhibitor compounds are used, then the disease symptoms can be temporarily relieved, but the in vivo exposure time is short and the drugs are rapidly eliminated
Solution Approach 1:
The patent modifies the chemical structure of elastase inhibitors by introducing specific substituents (R1-R6 groups) and molecular weight adjustments to change pharmacokinetic parameters. The compound structure is optimized to achieve extended half-life and prolonged in vivo exposure while maintaining elastase inhibitory activity, directly resolving the contradiction between short exposure time and therapeutic efficacy.
2Manufacturing precision
If complex purification processes are used to achieve high purity products, then product quality is improved, but production cost and complexity increase
Solution Approach 1:
The patent employs readily available commercial reagents and catalysts (e.g., boronic acid, trifluoroacetic acid, EDCI, HOBt) that can be easily handled and disposed of, simplifying the production process. The reaction conditions are designed to be straightforward with minimal specialized equipment required, achieving high purity products through simple filtration and concentration steps rather than complex purification sequences.
Solution Approach 2:
The patent optimizes reaction parameters (temperature, solvent ratios, reagent equivalents) to maximize product purity directly in the reaction mixture, minimizing the need for extensive purification. By controlling reaction conditions precisely, the process achieves high purity elastase inhibitors with simple workup procedures involving only filtration and concentration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process results in a high-purity elastase inhibitor with improved in vivo exposure and extended half-life, suitable for industrial production and effective in treating chronic obstructive pulmonary disease.
Implementation Method 1
reacting Compound 10 in the presence of a borylation reagent, an acidification reagent and a reaction solvent to obtain the compound of formula (I)
Implementation Method 2
A process for preparing an elastase inhibitor compound using specific borylation, acidification, and condensation reactions
Data Source
AI summary
The present disclosure relates to a process for preparing an elastase inhibitor compound. The process is: friendly to the environment, simple in operation, highly efficient, mild in reaction conditions, easy to control in operation, safe and reliable, low-cost and good in economic benefits. Meanwhile, the process provided in present disclosure offers a high reaction yield and a high purity for the obtained product, thus being suitable for industrial production.